A zebrafish model for pyruvate dehydrogenase deficiency: rescue of neurological dysfunction and embryonic lethality...

Area of Science:

• Biochemistry
• Developmental Biology
• Genetics

Background:

• Pyruvate dehydrogenase (PDH) complex defects lead to severe neurological dysfunction, congenital lactic acidosis, growth retardation, and early mortality.
• Current postnatal treatments for PDH deficiency are largely unsuccessful, highlighting the need for effective pre- and postnatal therapeutic strategies.

Purpose of the Study:

• To establish a zebrafish model for pyruvate dehydrogenase deficiency (PDD) to develop effective therapies.
• To investigate the therapeutic potential of ketogenic substrates for PDD.

Main Methods:

• A behavioral genetic screen identified zebrafish mutants with visual defects, including the 'no optokinetic response a' (noa) mutant.
• The noa mutant was identified as deficient in dihydrolipoamide S-acetyltransferase (Dlat), the PDH E2 subunit.
• Zebrafish embryos were treated with ketogenic substrates in their developmental water.

Main Results:

• The noa mutant exhibited phenotypes consistent with human PDD, including neurological dysfunction and lactic acidosis.
• Ketogenic substrate treatment rescued visual function, promoted feeding behavior, reduced lactic acidosis, and increased survival in noa mutant embryos.
• The study successfully demonstrated a therapeutic approach for PDD using ketogenic substrates.

Conclusions:

• Zebrafish with Dlat deficiency serve as a valuable model for studying PDH deficiency.
• Ketogenic substrate supplementation is a promising therapeutic strategy for PDH deficiency and potentially other congenital metabolic disorders.
• This research provides a foundation for developing novel pre- and postnatal therapies for early embryonic diseases.